GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q4 FY26 results · Jan–Mar 2026
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹995.30 crore (up 2.1% from Q4 FY25) and net profit of ₹277.86 crore (up 5.7% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 995.30 | 974.37 | +2.1% | 1,041.26 | −4.4% |
| Other income | 35.95 | 40.68 | −11.6% | 32.12 | +11.9% |
| Total income | 1,031.25 | 1,015.05 | +1.6% | 1,073.38 | −3.9% |
| Profit before tax | 373.10 | 358.57 | +4.1% | 399.93 | −6.7% |
| Net profit for the period | 277.86 | 262.87 | +5.7% | 295.62 | −6.0% |
| EPS, basic (₹) | 16.40 | 15.52 | +5.7% | 16.54 | −0.8% |
| Net margin (%) | 27.9 | 27.0 | 28.4 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 989.15 | 966.08 | +2.4% | 1,022.59 | −3.3% |
| Other income | 35.71 | 39.46 | −9.5% | 31.82 | +12.2% |
| Total income | 1,024.86 | 1,005.54 | +1.9% | 1,054.41 | −2.8% |
| Profit before tax | 369.12 | 354.90 | +4.0% | 377.89 | −2.3% |
| Net profit for the period | 274.94 | 260.14 | +5.7% | 277.18 | −0.8% |
| EPS, basic (₹) | 16.23 | 15.35 | +5.7% | 16.36 | −0.8% |
| Net margin (%) | 27.8 | 26.9 | 27.1 |
Consolidated
- Filed with BSE
- 13 May 2026, 22:15 IST
- Board meeting
- 13 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 May 2026, 22:15 IST
- Board meeting
- 13 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE